Surgery – Diagnostic testing
Reexamination Certificate
2011-06-14
2011-06-14
Johnson, III, Henry M (Department: 3769)
Surgery
Diagnostic testing
C128S920000, C705S003000, C235S375000
Reexamination Certificate
active
07959566
ABSTRACT:
Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
REFERENCES:
patent: 5299121 (1994-03-01), Brill et al.
patent: 5594637 (1997-01-01), Eisenberg et al.
patent: 5619991 (1997-04-01), Sloane
patent: 5660176 (1997-08-01), Iliff
patent: 5758095 (1998-05-01), Albaum et al.
patent: 5832449 (1998-11-01), Cunningham
patent: 5845255 (1998-12-01), Mayaud
patent: 5974203 (1999-10-01), Tadokoro et al.
patent: 6014631 (2000-01-01), Teagarden et al.
patent: 6045501 (2000-04-01), Elsayed et al.
patent: 6055507 (2000-04-01), Cunningham
patent: 6063026 (2000-05-01), Schauss et al.
patent: 6128620 (2000-10-01), Pissanos et al.
patent: 6131090 (2000-10-01), Basso, Jr. et al.
patent: 6202923 (2001-03-01), Boyer et al.
patent: 6315720 (2001-11-01), Williams et al.
patent: 6561976 (2003-05-01), Elsayed et al.
patent: 6561977 (2003-05-01), Williams et al.
patent: 6755784 (2004-06-01), Williams et al.
patent: 6767326 (2004-07-01), Elsayed et al.
patent: 6869399 (2005-03-01), Williams et al.
patent: 6908432 (2005-06-01), Elsayed et al.
patent: 2005/0090425 (2005-04-01), Reardan et al.
patent: 2005/0216309 (2005-09-01), Reardan et al.
patent: 2005/0222874 (2005-10-01), Reardan et al.
patent: 2006/0129433 (2006-06-01), Koneru
patent: 2 352 619 (2003-01-01), None
patent: 98/13783 (1998-04-01), None
patent: 98/58338 (1998-12-01), None
patent: 99/10829 (1999-03-01), None
patent: 00/51053 (2000-08-01), None
patent: 02/35440 (2002-05-01), None
Transcript, Thalidomide: Potential Benefits and Risks, an open public scientific workshop, Sponsored by National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention, Sep. 9, 1997.
Uhl, K. et al., “Thalidomide Use in the US: Experience with Pregnancy Testing in the S.T.E.P.S.® Programme,”Drug Safety, 2006, 29(4), 321-329.
Thalomid information from Drugs.com [online], Drugs.com, Jun. 22, 2006 [retrieved on Feb. 1, 2008], Retrieved from the internet: <URL: http://www.drugs.com/thalomid.html>.
Medical Marketing&Media, “Managing a product under attack: a firsthand report on Clozaril: Interview with Sandoz Ltd.'s director of product marketing, Barbara Rosengren and assistant director Gilbert Honigfeld,” Sep. 20, 1991,vol. 26, No. 10, p. 6.
Pastuszak, A. et al., “Use of the Retinoid Pregnancy Prevention Program in Canada: Patterns of Contraception Use in Women Treated With Isotretinoin and Etretinate,”Reproductive Toxicology, 1994, 8(1), 63-68.
Sittig, D. F. et al., “Computer-based Physician Order Entry: The state of the Art,”J. Amer. Med. Inform. Assoc., Mar./Apr. 1994, 1(2), 108-123.
Mitchell, A. A. et al., “A Pregnancy-Prevention Program in Women of Childbearing Age Receiving Isotretinoin,”N. Engl. J. Med., Jul. 13, 1995, 333(2), 101-106.
Trussell, J., “Contraceptive Efficacy,”Arch. Dermatol., Sep. 1995, 131, 1064-1068.
Honigfeld, G., “Effects of the Clozapine National Registry System on Incidence of Deaths Related to Agranulocytosis,”Psychiatric Services, Jan. 1996, 47(1), 52-56.
“Thalidomide protocols and patient materials designed by FDA for studies without commercial sponsors,” “The Pink Sheet”, Nov. 18, 1996, 58(047), p. T&G-4.
Physician's Desk Reference, 1997, pp. 2252-2254, 2377-2380.
FDA's Forty-Seventh Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee, Sep. 4-5, 1997.
Thalidomide: Potential Benefits and Risks. An Open Public Scientific Workshop, Program and Abstracts, Sep. 9-10, 1997.
Thalidomide: Potential Benefits and Risks. An Open Public Scientific Workshop, Transcript: NIH Testimony from Sep. 9, 1997: http://www.fda.gov/oashi/patrep
ih99.html.
Thalidomide: Potential Benefits and Risks. An Open Public Scientific Workshop, Transcript: NIH Testimony from Sep. 10, 1997: http://www.fda.gov/oashi/patrep
ih910.html.
Janet Woodcock, Director, Center for Drug Evaluation and Research, “Supervisory Review of NDA 20-785,” Jul. 7, 1998.
“Hoechst Arava Pregnancy Registry Recommended to Track Teratogenicity,” “The Pink Sheet”, Aug. 17, 1998, vol. 60, No. 033, p. 23.
Reference Guide “THALIDOMID™ (thalidomide): Clinical Information and Prescribing Guidelines,” Celgene Corporation, Sep. 1998.
Bates, D. W. et al., “Effect of Computerized Physician Order Entry and a Team Intervention on Prevention of Serious Medication Errors,”JAMA, Oct. 21, 1998, 280(15), 1311-1316.
System for Thalidomide Education and Prescribing Safety, “THALIDOMID™ (thalidomide): Balancing the Benefits and the Risks,” Celgene Corporation, Nov. 1998.
Zeldis, J. B. et al., “S.T.E.P.S.™: A Comprehensive Program for Controlling and Monitoring Access to Thalidomide,”Frontiers in Fetal Health: A Global Perspective, The Fetal Centre at the Hospital for Sick Children, Toronto, Canada, vol. 1, No. 2, Aug. 1999.
Roche's Press Release Regarding Pregnancy Prevention Program for Women for Women on Accutane, Oct. 31, 2001.
Villahermosa, L. G. et al., “A Randomized, Double-Blind, Double-Dummy, Controlled Dose Comparison of Thalidomide for Treatment of Erythema Nodosum Leprosum,”Am. J. Trop. Med. Hyg., 2005, 72(5), 518-526.
Uhl, K. et al., “Thalidomide Use in the US: Experience with Pregnancy Testing in the S.T.E.P.S.® Programme,”Drug Safety, 2006, 29(4), 321-329.
“About the CNR,” Website Printout: https://www.clozarilcare.com/care/NewUsrReqPersonal.jsp.
Complaint filed Jan. 18, 2007 in NJ:Celgene Corp. v.Barr Laboratories, Case No. 2:07-cv-00286-PGS-RJH.
Defendant Barr Laboratories, Inc.'s Answer, Counterclaims and Demand for Jury Trial filed Mar. 1, 2007 in NJ:Celgene Corp. v.Barr Laboratories, Case No. 2:07-cv-00286-PGS-RJH.
Fax sent Oct. 14, 2004 from Ian Hilley of GenPharm, Inc. To John Jackson of Celgene Corp. re: Isotretinoin Pregnancy Risk Management Program.
Press Release dated Nov. 23, 2004, “Isotretinoin Makers Reach Agreement with Celgene on S.T.E.P.S. Risk Management Patents,”.
Notification letter dated Dec. 5, 2006 from Sterne Kessler to Celgene Corporation re: Notification Pursuant to § 505(j)(2)(B)(ii) of the Federal Food, Drug and Cosmetic Act.
Notification letter dated Dec. 15, 2006 from Sterne Kessler to Celgene Corporation re: Supplemental Notification Pursuant to § 505(j)(2)(B)(ii) of the Federal Food, Drug and Cosmetic Act.
Notification letter dated Dec. 19, 2006 from Sterne Kessler to Celgene Corporation re: Supplemental Notification Pursuant to § 505(j)(2)(B)(ii) of the Federal Food, Drug and Cosmetic Act.
Bakken, K., et al., “Local monitoring center for clozapine therapy: quality assurance of drug treatment in a group of psychiatric patients,”Tidsskr nor Laegeforen nr., 1998, 118, 1076-1078 (English abstract middle of p. 1076).
Bastani, B., et al., “Development of the clozaril patient management system,”Psychopharmacology, 1989, 99, S122-S125.
Behm, G.A., Jr., No Title,Am. Pharmacy 13thAPhA Annual Meeting Highlights, 1990, NS30(6), p. 7.
Bender, K.J., “FDA approves reduced clozapine monitoring; increased patient access versus increased risk,”Psychiatric Times, 1998, vol. XV, Issue 5.
Black, L.L., et al., “A centralized system for monitoring clozapine use in British Columbia,”Psychiatr
Kaminski Joseph K.
Williams Bruce A.
Celgene Corporation
Johnson, III Henry M
Rajan Kai
Woodcock & Washburn LLP
LandOfFree
Methods for delivering a drug to a patient while restricting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for delivering a drug to a patient while restricting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for delivering a drug to a patient while restricting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2639396